BioSource board spurns Bio-Rad offer
This article was originally published in Clinica
Executive Summary
The board of directors of BioSource International has voted unanimously to reject Bio-Rad's $8.50 per share unsolicited takeover bid for the company (see Clinica No 1152, p 13). It decided that the offer was "significantly below BioSource's inherent value", following consultation with legal and financial advisors.